Cancer survivors treated with chemotherapy frequently complain about impairment of cognitive functions including attention and memory. While the contribution of factors like psychological distress, anxiety or fatigue to this "chemobrain" syndrome has been discussed, studies in rodents have demonstrated the toxicity of various chemotherapeutic substances to the adult central nervous system. In humans, structural brain imaging has revealed both reduced gray and white matter volume and decreased white matter integrity related to chemotherapeutic treatment. Studies of brain function have found alterations in brain activation patterns during different types of tasks. Nevertheless, further clinical research using prospective designs in larger samples is required to better understand the relationship between chemotherapy and cognitive deficits. Variables that need to be considered more systematically include drug dose, genetic variations, and psychological factors. Assessing both electroencephalographic and hemodynamic responses during tasks at different stages of the processing hierarchy and at di erent di culty levels should help in pinpointing the cortical processes a ected by chemotherapy. 
Many
cancer patients treated with chemotherapy report symptoms related to cognitive impairment. The most frequently affected functions include memory, attention, processing speed and multitasking [1] [2] [3] . This syndrome, which has been termed "chemobrain"
or "chemo fog", significantly impairs the quality of life of patients undergoing active therapy and cancer survivors. It has been studied most extensively in the population of breast cancer patients with an estimated frequency of 20-40% of affected patients [4] . Cognitive dysfunction is revealed both by patients' self-reports and by neuropsychological tests, although both types of measures do not necessarily correlate with each other [5, 6] .
Most cognitive de cits tend to recover within the first year after treatment; however, some studies have convincingly demonstrated longterm effects years after treatment [7] . While the respectively, may at least in part account for the cognitive sequelae of chemotherapy [14] .
Additional evidence for this notion has been provided by an increasing number of animal studies using behavioral paradigms [15, 16] .
Exposure to chemotherapeutic agents was associated with decreased performance on different types of learning tasks utilizing hippocampal and frontal network functions [17] [18] [19] [20] .
Structural and functional brain imaging studies have started to elucidate the neural correlates of chemotherapy-related cognitive decline in humans [21] [22] [23] [24] . Examinations of cortical structure using magnetic resonance imaging (MRI) have demonstrated reductions of both gray and white matter volume when comparing chemotherapy-treated patients with either healthy controls [25] or untreated patients [26] . Prospective studies have revealed that both frontal and temporal cortex showed the most pronounced volume reductions [27, 28] . A recent cross-sectional investigation provided evidence for hippocampal damage that was related to decreased verbal memory performance [29] . In line with the findings from the animal work reported above, diffusion tensor imaging (DTI) studies have found chemotherapy-related reductions of white matter integrity that correlated with cognitive performance [30] . A prospective DTI study Paradigms included verbal long-term memory [37, 38] , verbal working memory [39, 40] , and tasks requiring rule testing or planning, both involving prefrontal cortex [41, 42] . Activation 
